Acción VYGR VOYAGER THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Voyager Therapeutics, Inc.

Acciones

VYGR

US92915B1061

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
7,8 USD -0,26 % Gráfico intradía de Voyager Therapeutics, Inc. -4,41 % -7,58 %
13/06 Voyager Therapeutics, Inc. Nombra a Nathan Jorgensen Director Financiero, y Director de Contabilidad, con efecto a más tardar el 8 de julio de 2024 CI
16/05 Voyager Therapeutics, Inc anuncia la dosificación de los primeros participantes en el ensayo de dosis única ascendente de VY-TAU01 para el tratamiento de la enfermedad de Alzheimer CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics Names Nathan Jorgensen as Finance Chief
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Principal Financial Officer, and Principal Accounting Officer, Effective No Later Than July 8, 2024
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer?s Disease
Voyager Therapeutics: Q1 Earnings Snapshot
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER??-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer
Voyager Therapeutics, Inc. Announces CFO Changes
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción VYGR
  4. Noticias Voyager Therapeutics, Inc.
  5. Otros idiomas